Dr.Elizabeth Jacobs, MD/MAPP, Healthcare Research and Policy, MaineHealth

Dr. Liz is the Associate Chair for Research, Department of Internal Medicine at Dell Medical, and VP for Research at MaineHealth, a not-for-profit family of high-quality providers and health care organizations in Maine recognized as one of the US's top integrated health care delivery networks. Dr. Liz previously served as Chief of Primary Care at Dell and prior to joining Dell Medical School, she was a professor of medicine and population health sciences and vice chair for health services research in the Department of Medicine at the University of Wisconsin School of Medicine and Public Health.

Dr. Jacobs’ research interests include access to, and cultural specificity of, medical care delivered to patients, the impact of interpreter service interventions on the cost and quality of healthcare, health literacy, and numeracy, and the role that trust in health care plays in racial/ethnic disparities in health care. Her research has been supported by grants from the National Cancer Institute, the National Institute on Aging, The Robert Wood Johnson Foundation, The California Endowment, The Russell Sage Foundation, The Patient-Centered Outcomes Research Institute, and the Office of Minority Health.

She has served on the Office of Minority Health, Joint Commission, National Quality Forum, Patient-Centered Outcomes Research Institute, and AHRQ expert panels. She received the Chancellor's Community-Academic Partnership Award, 2017, University of Wisconsin System; Outstanding Investigator Award, 2017 School of Medicine and Public Health, University of Wisconsin, and Addis Costello Award, 2014, American College of Physicians Wisconsin Chapter. She attended medical school at the University of California at San Francisco and trained as a general internist at Brigham and Women’s Hospital in Boston. She completed a Robert Wood Johnson Clinical Scholars fellowship and a master’s in public policy at the University of Chicago.

Richard J Siemens

His Excellency Marwan Bin Jassim Al Sarkal

Chairman, Shurooq

  • Grey LinkedIn Icon

His Excellency Marwan bin Jassim Al Sarkal is the Executive Chairman of the Sharjah Investment and Development Authority (Shurooq), an entity tasked with leading the continued transformation and economic diversification of the emirate of Sharjah. Named as the Middle East CEO by the prestigious Burj CEO Awards and chosen as one of '100 most Powerful Arabs' by Arabian Business magazine, HE Marwan is one of the key business leaders in the UAE to drive and lead the investment and cultural growth of Sharjah. His career with Shurooq began as CEO of the authority in 2009 at the time of its establishment under an Emiri decree by His Highness Sheikh Dr. Sultan bin Muhammad Al Qasimi, Member of the Supreme Council and Ruler of Sharjah. HE Marwan bin Jassim Al Sarkal has played an integral role in transforming Sharjah's economic infrastructure, diversifying markets, and facilitating new investments by major developments covering environment, healthcare, logistics, tourism, light manufacturing, education, real estate, aquaculture, agriculture, mobility, and AI. He has spearheaded major infrastructural projects and key partnerships at Shurooq estimated at a total value of more than AED 10 billion. 

 

His creative, innovative thinking and futuristic approach, rooted in the emirate's traditions and history, have enabled Shurooq to adopt world-class standards. With his exceptional commitment to diversity, training, gender inclusivity, and continuous learning, Marwan has enabled an open, creative, and innovative environment that designs projects for future generations. He is also a board member of several organizations and has won countless accolades including the FDI Environmentally Sustainable Developments Industry during the European CEO Awards. 

 

An avid traveler and technology enthusiast, HE  Marwan bin Jassim Al Sarkal holds a BAS in Accounting and Business Administration.

C. Richard Piazza

Chairman, Qsam Pharmaceuticals

C. Richard Piazza, Ph.D. is a seasoned healthcare executive with 48 years of global experience in the medical device, biotech, and pharma. His 44 years in general management positions encompass business growth & adoption, spearheading M&A, JV, Board experience in both public (NASDAQ, AMEX, TSX, DAX, TASE, FWB) and private companies including Ohmeda (BOC, now Linde Group), Smith & Nephew Pharma, Marquest & VitaGen (world’s first bioartificial liver). He has an invaluable drug, biologic, device development & clinical trial experience, regulatory approvals for levels of products- Class I, II & III devices, BLA, NDA & ANDAs with clinical sites included both domestic and international sites.

Richard, highly regarded in TMC  is an industry representative working with the FDA and Congress to craft the FDA Modernization Act for Medical Devices and served on industry association boards & committees (Advamed, Biocomm, Bio Houston). In addition to industry affiliations, Richard remains committed to working with well-known medical pioneers, “world-class,” teams, and to identify, and advance new technologies to bring them to fruition. He acts as an advisor to some of the world’s leading institutions such as MD Anderson Cancer Center, Baylor College of Medicine, University of California San Diego, University of Chicago & Kings College Hospital (London.) Richard has been a Guest Lecturer in Sales & Marketing strategy at numerous Universities including Rice University School of Management, UCLA, University of Wisconsin, CAL Tech-MIT forum, University of British Columbia & University of California San Diego. In 2019 he co-founded QSAM Therapeutics, Inc. with Doug Baum and currently serves as its Executive Chairman.

Leo Womack

Leo B. Womack Family Trust

Leo has served as a Houston business leader for 30+ years and owns Ramsey Financial Group (RFG), a Texas-based single-family office established since 1992. RFG seeks to preserve wealth, deploy capital into the most viable, long-term, wealth-building opportunities that have good risk-to-reward metrics. Portfolio industries include public and private companies in space tech, real estate, life sciences, medical devices, agri-tech, and more. Leo started his career with Arthur Anderson to buy a CPA firm in Texas Medical Centre that grew into a large private CPA firm to finally merge it with Fox & Co to be the partner in Houston. Meanwhile, he had co-founded the 376-bed Park Plaza Hospital with 140 physician partners, and a surgery center company that built 12 centers regionally to sell it to an NYSE Hospital Management company for over $100mn. He is the chairman at Monebo, Artella (previously CorVitals), patented Mobile Cardiac Telemetry (MCT) for EKGs. He also is a board member for Eden Grow Systems, an agri-tech firm, the SpaceTech Fund, and more. Leo co-founded Gulf Equities Realty Advisors and is a co-founder of the Houston Angel Network, the most active and oldest angel network in the US with over $400M in 100 companies to foster innovation and entrepreneurship. 

Leo's close associate running BCMT at Baylor, Steve Banks got Leo into Fairway Medical Technologies to grow the practice. FMT is a business to design, develop, manufacture, and commercialize medical devices and technologies. Steve broke ground in investments with Henry Hillman in the '70s particularly in biopharma deals such as Genentech or HybriTech (acquired by Lilly).

Richard J. Siemens,

Chairman, Distacom 

Mr. Siemens, also known as the Father of Mobile Telephony and ORANGE, played an instrumental role in the telecommunications and broadcasting industries. Born and raised in Canada, trained as Chartered Accountant, he joined Distacom Communications in 1973 to build the largest paging company in western Canada before moving to Hong Kong to start Advance Telecom Services (ATS). In 1984, he formed Hutchison Telephone (HT), a partnership between Distacom, Hutchison Whampoa, and Motorola that saw US$100 million annually. In 1990, together with Cable & Wireless and CITIC Pacific, he built AsiaSat, the first satellite company in Asia plus and spearheaded Hutchison's telecom business in the UK, later known as the ORANGE network, 14 countries with 1+ million subscribers and 6K employees.

He was Co-Chairman and Exec Director of SUNDAY Communications Limited, a company listed on both Hong Kong Stock Exchange and NASDAQ, acquired by PCCW in 2005. Mr. Siemens was the Chairman of e-KONG Group Ltd, a company listed on the main board of the Hong Kong Stock Exchange (SEHK: 524).

He re-launched Distacom as an independent company, acquiring new assets and focusing on developing wireless networks in new markets. He is currently the Chairman of Distacom Group and the non-executive Chairman of Sprintex Limited, a company listed on the Australian Stock Exchange, that manufactures patented superchargers used in the automotive and related industries globally.

Rick collaborated with a few great minds at Distacom including  Simon Murray.

Dr. Neil Campbell,

Board, Life Sciences Pennsylvania

MD, Mosaigen

A global C-level entrepreneurial executive with 25+ years of success building public and private businesses in science & technology sectors with a strong focus on the life sciences through the commercialization of over 290 products and services. Neil started his career with Abbot Labs, IGEN (Now Roche) and spent an executive career with private VC/PE international investment fund experience as a general partner and advisor and has advised HNWI, FOs, VC, and PE funds with board practice advisory services and helped build start-ups to Fortune 500 providing leadership in turnarounds, stagnant growth, emerging-growth, and developing country. Dr. Campbell runs Mosaigen, founded in 2004 as a global technology development corporation specializing in the life sciences, ICT, and Cleantech industries using a unique model "reverse startup" approach.  This includes Nanotechnology & Material Sciences, Life Sciences (Pharma, Device, Diagnostics, Research, OTC/CPG), ICT (High-performance computing, Web 2.0, Machine Learning, Pattern Recognition/Dynamic Scaffolding, Virtualization platforms, Simulation, Physics Engines, and New Media), and lastly Clean/Green Tech (Solar, Wind, Smart Software, Materials, renewable Energy, non-food stock biofuels & ISBEs). 
Neil has capital market experience from seed to IPO with over $420M directly raised and involved in roadshow teams for IPOs totaling > $1B. He is on the Investment Committee for Genomic Medicine Catalyst Investment Fund, UK. He is a scholar-practitioner, author, and speaker on innovation, entrepreneurship, and capital appreciation methods for science & technology commercialization. Neil received his doctorate from University of Liverpool, UK  and MBA & MS from  Webster. 

Rohit Hegde,

Board Member, Aequs Consumer

Head India, Inflexion 

Rohit has spent several years in three continents building portfolio companies of Private Equity Firms, a large engineering company, and a technology firm company. Rohit ran his own auto components business Adeep Group in India sold to Actis Private Equity in 2006. At the time of sale, Adeep was a $25M company with 1300 employees in the business of manufacturing locksets, wheel rims, clutch assemblies & fuel taps.

Between 1993 and 1998 Rohit managed Hewlett Packard's Medical Supplies Manufacturing business in Andover, MA, USA. From 1983 to 1992 Rohit managed the manufacturing activities of Scully Signal Company manufacturing heating oil delivery systems in Wilmington, MA. He is well-connected and highly experienced in helping European and British companies develop their operations in India. He delivers targeted market development plans to support portfolio company activities in India and helps with investment team decisions. Currently a Member of the board and an investor in Aequs Consumer, a subsidiary of Aegus Global.

Rohit has an MBA from Northeastern University, Boston, an MS in Industrial Engineering from Texas Tech University, and a BS in Mechanical Engineering from Anna University, Chennai. Rohit is passionate about the opportunities India offers to ambitious companies however when not at work he enjoys swimming and basketball and is a fiercely competitive tennis player. 

Parwez Jugoo,

Barrister at Law,ex-Group Legal Counsel

 Airtel & Zain

Parwez is ex-Group Legal Counsel for Airtel Africa that acquired assets of Zain Telecom in Africa who pursued law at the University of Mauritius and is a barrister of the Bar of Mauritius. He was a pupil of Lord Marks QC of the Inner Temple, England, and of Nicolas Sorensen of the Barreau d’Aix-en-Provence, France.

 

He is an expert in the telecommunications industry and has earned valuable experience for 30+ years, as a legal adviser to large telecom multi-nationals and in this capacity, he participated in numerous bids for telecoms licenses worldwide and was part of M&A teams during major transactions in those telecom groups. He was the ex-CEO of MADACOM, Madagascar, (now Airtel) where he helmed the company into a USD 100MN successful business prior to selling the company to Zain. A seasoned team leader, he has served with teams of PWC and he served was the ex-legal counsel with Celtel, and Zain (MTC group). He has acted as a legal advisor to the Distacom Group that owned Orange (now PCCW) in Hong Kong, Spice Telecom in India, and MADACOM S.A. in Madagascar. Parwez advised GSM license bids in Ivory Coast, DRC, Mayotte, Comoros, Anjouan, Mauritius, South Africa, and Lebanon. Until recently he was recently a team member at Benoit Chambers, a leading law firm in Mauritius.

He has an advanced Management course from London Business School. Parwez is excellent in English and French.

Rashmi Kilam

Founder, MD Bouin Capital

Member of Advisory Board, Enlivity

Rashmi spent 20 years of building teams and businesses across 20+ countries in EMEA and the Asia Pacific. Her career started in the dot com era with a holding company, Distacom that built Orange, J-Phone (now Softbank), StarTV, and the Hutchison group. At their subsidiary, Asia Pacific Capital, Rashmi worked with their internet business and became the core team for their first B2B software acquisition that had a unicorn exit in Finland. She also collaborated with their other investments, NASDAQ listed SUNDAY of Hong Kong (now PCCW) for catalyzing their GSM award, Blu SpA Italy (sold to Telecom Italia), and Spice Telecom in 2000 where she was trained in telecom billing and payment system.

 

Rashmi started the roots of Bouin Capital with an M&A advisory practice (acquired), Edelweiss Capital (IPO), and three IT & BPO companies. She has served multiple advisory boards, reviewed numerous business plans, and built her portfolio of investments from healthcare, fintech, cleantech, and beyond. Rashmi has actively advised family offices, angel groups, and is with the South West Angel Network, an impact-only member of Angel Capital Association. She is an ambassador for HITLab NY, an impact organization to help shape the future of healthcare, and a venture mentor with the University of Texas, Women in Healthcare HLTH Foundation, and MassChallenge Boston. Rashmi earned MBA and ranked 2nd in her BSc in Biology & Chemistry from Delhi University 1995.

Rashmi Kilam

We empower teams to build impactful and resilient organizations
  • LinkedIn Social Icon
  • Facebook Social Icon